Bauer AJ, Auble B, Clark AL, et al. Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review. Front Pediatr. 2024;12:1–11.

Google Scholar 

Markova B, Mayerl S, Heuer H. Toward a treatment for thyroid hormone transporter MCT8 deficiency - achievements and challenges. Eur Thyroid J. 2024;13(6):1–9.

Google Scholar 

European Medicines Agency. Emcitate 350 microgram dispersible tablets: summary of product characteristics. 2025. https://ec.europa.eu/. Accessed 7 Mar 2025

Egetis Therapeutics. European Commission approves Egetis' Emcitate(Rm) (tiratricol) as the first and only treatment for patients with MCT8 deficiency [media release]. 13 Feb 2025. http://www.egetis.com.

European Medicines Agency. CHMP summary of positive opinion for Emcitate. 2024. https://www.ema.europa.eu/. Accessed 7 Mar 2025

Sonesson C, Carroll K, Singh N, et al. The first robust bioavailability/bioequivalence (BA/BE) study of thyromimetic tiratricol, a treatment in development for MCT8 deficiency. Horm Res Paediatr. 2024;97(Suppl. 3):77.

Google Scholar 

Chan SL, Refetoff S, Babic N, et al. Triiodothyroacetic acid cross-reacts with measurement of triiodothyronine (T3) on various immunoassay platforms. Am J Clin Pathol. 2022;157(2):156–8.

CAS  PubMed  Google Scholar 

Freund M, Chatterjee K, van Geest F, et al. Effects of tiratricol treatment withdrawal in MCT8 deficiency: ReTRIACt Trial [abstract no. T2]. Horm Res Paediatr. 2023;96(Suppl. 4):124–5.

Google Scholar 

Egetis Therapeutics. Egetis has decided to explore RTH-beta as the next indication for tiratricol (Emcitate)(R) [media release]. http://www.egetis.com. 4 Dec 2024

PledPharma. PledPharma completes the acquisition of Rare Thyroid Therapeutics [media release]. 3 Nov 2020. http://www.pledpharma.com.

PledPharma. PledPharma changes its name to Egetis Therapeutics with focus on late stage orphan drug development [media release]. 17 Dec 2020. http://www.pledpharma.com.

Egetis Therapeutics, Fujimoto Pharmaceutical Corporation. Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan [media release]. 10 Nov 2023. http://www.egetis.com.

Egetis Therapeutics. Egetis submits a patent application to the United States Patent and Trademark Office for "Processes of Preparation" of tiratricol [media release]. 19 Sept 2024. http://www.egetis.com.

Messier N, Langlois MF. Triac regulation of transcription is T(3) receptor isoform- and response element-specific. Mol Cell Endocrinol. 2000;165(1–2):57–66.

CAS  PubMed  Google Scholar 

Horn S, Kersseboom S, Mayerl S, et al. Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter Mct8. Endocrinology. 2013;154(2):968–79.

CAS  PubMed  Google Scholar 

Kersseboom S, Horn S, Visser WE, et al. In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency. Mol Endocrinol. 2014;28(12):1961–70.

PubMed  PubMed Central  Google Scholar 

Salas-Lucia F, Escamilla S, Bianco AC, et al. Impaired T3 uptake and action in MCT8-deficient cerebral organoids underlie Allan-Herndon-Dudley syndrome. JCI Insight. 2024;9(7):1–16.

Google Scholar 

Chen J, Salveridou E, Liebmann L, et al. Triac treatment prevents neurodevelopmental and locomotor impairments in thyroid hormone transporter Mct8/Oatp1c1 deficient mice. Int J Mol Sci. 2023;24(4):3452.

CAS  PubMed  PubMed Central  Google Scholar 

Reinwald JR, Weber-Fahr W, Cosa-Linan A, et al. TRIAC treatment improves impaired brain network function and white matter loss in thyroid hormone transporter Mct8/Oatp1c1 deficient mice. Int J Mol Sci. 2022;23(24):1–19.

Google Scholar 

Grijota-Martínez C, Montero-Pedrazuela A, Hidalgo-Álvarez J, et al. Intracerebroventricular high doses of 3,3′,5-triiodothyroacetic acid at juvenile stages improve peripheral hyperthyroidism and mediate thyromimetic effects in limited brain regions in a mouse model of monocarboxylate transporter 8 deficiency. Thyroid. 2023;33(4):501–10.

PubMed  Google Scholar 

Groeneweg S, Peeters RP, Moran C, et al. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(9):695–706.

CAS  PubMed  PubMed Central  Google Scholar 

van Geest FS, Groeneweg S, van den Akker ELT, et al. Long-term efficacy of T3 analogue Triac in children and adults with MCT8 deficiency: a real-life retrospective cohort study. J Clin Endocrinol Metab. 2022;107(3):e1136–47.

PubMed  Google Scholar 

Egetis Therapeutics. Egetis announces topline results of the phase 2 Triac Trial II with Emcitate(Rm) (tiratricol) for MCT8 deficiency [media release]. 19 June 2024. http://www.egetis.com.

European Medicines Agency. CHMP public assessment report (Emcitate). 2025. https://www.ema.europa.eu/. Accessed 31 Mar 2025